CRISPR Therapeutics has developed SyNTase editing, a proprietary, next-generation, site-specific gene correction platform.

CRISPR Therapeutics (CRSP) just announced that its SyNTase gene editing technology will be featured in an oral presentation at the ESGCT 2025 Congress. This marks the first major public unveiling of ...

Stanford researchers and their collaborators have revealed a new device that could change the way scientists conduct ...

CRISPR Therapeutics reports promising Phase 1 clinical data for CTX310™, with significant triglyceride and LDL reductions, and updates on other programs. CRISPR Therapeutics announced promising new ...

-CTX310™ led to durable reductions of angiopoietin-like 3 protein (ANGPTL3) and triglyceride levels in non-human primates (NHPs) after a single dose- CRISPR Therapeutics is advancing a pipeline of in ...

-Preliminary data demonstrate that CTX112™ has the potential to provide meaningful clinical benefit with a well-tolerated safety profile using a standard lymphodepletion protocol- -Company announced ...

CRISPR Therapeutics (CRSP) announced the acceptance of an abstract for oral presentation at the European Society of Gene and Cell Therapy, ESGCT, ...

Stanford Medicine researchers have developed an artificial intelligence tool to help scientists better plan gene-editing experiments. The technology, CRISPR-GPT, acts as a gene-editing "copilot" ...

ZUG, Switzerland and BOSTON, Sept. 09, 2025 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious ...

Today, Benzinga's options scanner spotted 14 options trades for CRISPR Therapeutics. This is not a typical pattern. The sentiment among these major traders is split, with 28% bullish and 42% bearish.